Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

A Papi¹
D Dakic²
W Tzimas³
I Meszaros⁴
A Olech-Cudzik⁵
Z Koroknai⁵
K McAulay⁷
S Mersmann⁵
PS Dalvi⁹
T Overend⁹

¹Department of Internal and CardioRespiratory Medicine, Research Center on Asthma and COPD, University of Ferrara, Ferrara, Italy; ²Clinic of Pulmology and Allergy, Clinical Centre, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Macedonia; ³Pneumologische Praxis, München, Germany; ⁴Coral Szakorvosi Centrum, Budapest, Hungary; ⁵Ostrowieckie Centrum Medyczne Spolka, Ostrowiec Swietokrzyski, Poland; ⁶PAREXEL International, Global Medical Services, Budapest, Hungary; ⁷Medical Operations, Mundipharma Research Limited, Cambridge, UK; ⁸Biostatistics and Clinical Data Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany; ⁹Medical Science - Respiratory, Mundipharma Research Limited, Cambridge, UK

Purpose: To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD.

Patients and methods: COPD patients with forced expiratory volume in 1 s (FEV₁) ≥50% predicted and ≥1 moderate/severe COPD exacerbation in the last 12 months were randomized to FP/FORM 500/20 or 250/10 μg bid, or formoterol (FORM) 12 μg bid for 52 weeks. The primary outcome was the annualized rate of moderate/severe COPD exacerbations.

Results: In total, 1,765 patients were randomized. There were fewer discontinuations with FP/FORM 500/20 μg (20.6%) and 250/10 μg (24.0%) compared with FORM (26.1%). None of the two FP/FORM doses reduced the moderate/severe exacerbation rate versus FORM (rate ratios [RR]: 0.93; P = 0.402). There was a trend toward a lower moderate/severe exacerbation rate with FP/FORM 500/20 μg versus FORM in patients with ≥2 exacerbations in the preceding year (RR: 0.79; P = 0.084). Pre- and post-dose FEV₁ and forced vital capacity were greater with FP/FORM 500/20 μg versus FORM (P ≤ 0.039). There was a trend toward a lower EXAcerbations of Chronic pulmonary disease Tool (EXACT) exacerbation rate with FP/FORM 500/20 μg versus FORM (RR: 0.87; P = 0.077). There were more St George’s Respiratory Questionnaire for COPD (SGRQ-C) responders with FP/FORM 500/20 μg than FORM (odds ratios [OR] at weeks 6, 23 and 52 ≥ 1.28; P ≤ 0.054). EXACT-respiratory symptoms total and breathlessness scores were lower with both FP/FORM 500/20 μg and 250/10 μg versus FORM (P ≤ 0.066). Acute β₂-agonist-induced effects and 24-hour Holter findings were similar for all treatments. Mean 24-hour urinary cortisol was similarly reduced with both FP/FORM doses. Radiologically confirmed pneumonia was seen in 2.4%, 3.2% and 1.5% of FP/FORM 250/10, 250/10 and 250/10 μg, respectively. Adverse events were otherwise similar across treatment groups.

Conclusion: FP/FORM did not reduce exacerbation rates versus FORM. Numerical benefits were observed with FP/FORM 500/20 μg versus FORM for secondary variables, including lung function, EXACT exacerbations, SGRQ-C and EXACT-respiratory symptoms total and breathlessness scores. Few efficacy differences were evident between FP/FORM 250/10 μg and FORM. Pneumonia was more frequent in FP/FORM-treated patients, although the absolute difference was low. Adverse events were otherwise similar between treatments.

Keywords: flutiform, chronic bronchitis, emphysema, exacerbations, eosinophils

Introduction

The primary goals of COPD management are the improvement of symptoms, exercise tolerance and health status, the prevention of disease progression and exacerbations, and mortality reduction.¹ Currently, inhaled corticosteroid/long-acting β₂-agonist combinations (ICS/LABAs) are recommended for the treatment of Global Initiative for Chronic Obstructive Lung Disease (GOLD) group C and D patients, that is, those at risk of exacerbations, given evidence of risk reduction from a number of trials.²⁻⁸
There is additionally much interest at present in eosinophilic and non-eosinophilic COPD phenotypes and a large ongoing trial may further define the role of ICS/LABAs and other treatment classes in the future.9

Flutiform® is a fixed combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI), which is licensed for use in asthma following a comprehensive series of clinical trials.10–19 The EFFECT trial (Efficacy of Fluticasone propionate/ Formoterol in COPD Treatment) was a Phase III study undertaken to evaluate the efficacy and safety of FP/FORM in COPD.

Methods
The methodology of the EFFECT trial has previously been reported.20 The trial is registered with the EU Clinical Trials Register (EudraCT Number: 2012–004162–17). The protocol and other relevant study documentation were formally approved in each country by central and/or local ethics committees (Supplementary materials, Table S1) before subjects were screened, and all subjects provided written informed consent prior to any study-specific procedures being performed.

Patients
Male and female COPD patients aged ≥40 years, with post-bronchodilator forced expiratory volume in 1 s (FEV1) ≤50% predicted and an FEV1/forced vital capacity (FVC) ratio <0.7, a history of at least 1 moderate or severe COPD exacerbation in the last 12 months (requiring systemic corticosteroids and/or antibiotics and/or hospitalization), and a minimum 10 pack-year smoking history were enrolled. Moderate or severe exacerbations at screening (or during the run-in period) rendered a patient ineligible. During the treatment period, prohibited medications included long-acting muscarinic antagonists, phosphodiesterase-4 inhibitors, xanthine derivatives, short-acting β-agonist/muscarinic antagonist combinations, oral β-agonists, non-selective β-blockers, maintenance acetylcysteine or carbocysteine, and systemic steroids (except those required for the short-term treatment of an exacerbation).

Study design
This was a randomized, parallel-group, double-blind study. Patients discontinued their existing COPD medications and received tiotropium dry powder inhaler (Spiriva®) 18 µg once daily during a 2-week run-in period. During the run-in, a baseline EXAcertations of Chronic pulmonary disease Tool (EXACT) score was determined. An electronic interface (Model 2120 In2itive™ eDiary [Vitalograph, Buckingham, UK]) was used to self-administer the EXACT daily. At the end of the run-in, patients were randomized to 52 weeks of treatment with FP/FORM pMDI 500/20 µg bid or 250/10 µg bid or formoterol (FORM) pMDI 12 µg bid (Atimos® Modulite®). Patients attended post-randomization visits at weeks 2, 6, 13, 23, 33, 43 and 52. The EXACT “baseline” score was continually reset throughout the 12-month study per EXACT user guidelines.21 When changes in EXACT symptom scores met validated exacerbation thresholds,21 alerts were sent to both the investigator (via email) and the patient (via the electronic diary) to prompt patient–physician contact and ascertain whether clinical review was necessary.

Outcomes
The primary outcome was the annualized rate of moderate-to-severe COPD exacerbations during the 52-week treatment period. Moderate events were those requiring treatment with systemic corticosteroids and/or antibiotics. Severe exacerbations were events requiring hospitalization or resulting in death. Events separated by at least 7 days were defined as 2 distinct exacerbations. A standardized regimen of 30–40 mg of prednisolone for 7–14 days (per GOLD 2014 guidelines) was recommended if oral corticosteroid treatment was considered necessary for exacerbation management.

Secondary outcomes included: the average pre- and 1-hour post-dose FEV1 and FVC over 52 weeks; the annualized rate of EXACT exacerbations; the time to first moderate or severe COPD exacerbation; the change in St George’s Respiratory Questionnaire for COPD (SGRQ-C) from baseline to weeks 6, 23, and 52; the proportion of SGRQ-C responders; daily rescue medication use (occasions/day); the percentage change in awakening-free nights from baseline over 52 weeks; and the average EXACT-respiratory symptoms (E-RS) breathlessness and total scores over 52 weeks. Changes from baseline to week 6 in surfactant protein-D (SP-D) and C-C motif chemokine ligand 18 (CCL-18) were also measured and their relationships with clinical outcomes were examined.

A number of post hoc outcomes were also defined to further evaluate the study data including: time to first clinically important deterioration (CID; deterioration defined as either a moderate or severe exacerbation, an increase in SGRQ ≥4 units or a decrease in FEV1 ≥100 mL);22 time to discontinuation; the distribution of baseline blood eosinophil counts; and the annualized rate of moderate or severe exacerbations dichotomized by baseline blood eosinophil counts. Two other exploratory
definitions of CID (incorporating differing combinations of FEV₁, SGRQ-C, moderate/severe exacerbation events and EXACT exacerbation events) were also evaluated.

Safety outcomes included: adverse event summaries; the incidence of radiologically- and clinically-defined pneumonia per British Thoracic Society (BTS) criteria; 24-hour Holter monitoring (in ~100 patients/arm); an assessment of β₂-agonist-induced safety effects (maximum reductions in serum potassium and diastolic blood pressure, maximum increments in heart rate, systolic blood pressure and QT interval) (in ~125 patients/arm); and 24-hour urinary cortisol estimation (in ~50 patients/arm without ICS exposure at screening).

Statistics

Assuming a 20% reduction in exacerbation rate with combination therapy, an exacerbation rate of 0.8 exacerbations/patient/year in the formoterol group, 5% of patients being excluded from the full analysis population, and a two-sided alpha of 5%, a sample size of 586 patients per treatment group was required.

The primary endpoint, the annualized rate of moderate/severe exacerbations was analyzed using a negative binomial regression model with fixed terms for treatment, FEV₁ % predicted category, number of exacerbations in the previous year category, smoking status, prior ICS use, and country, and the logarithm of time on treatment as an offset variable. A hierarchical gatekeeping procedure was employed to control for multiplicity given the 2 comparisons for the primary endpoint: the secondary comparison FP/FORM 250/10 µg versus FORM was analyzed in a confirmatory manner only if the primary comparison (FP/FORM 500/20 µg versus FORM) was significant at the 5% level. Control for multiplicity for pre-defined key secondary endpoints was done using a Hochberg closed testing procedure. The same negative binomial model was used to analyze exact exacerbations (but including baseline EXACT total score as an additional covariate) and post hoc analyses of exacerbations by baseline blood eosinophil count. Time to first moderate/severe exacerbation was analyzed with a Cox proportional hazards model with fixed terms for treatment, FEV₁ % predicted category, number of exacerbations in the previous year category, smoking status, prior ICS use and country. An identical model was used to analyze, post hoc, time to first CID. Spirometry, SGRQ-C, E-RS total and breathlessness scores were analyzed using repeated measures analysis of covariance with fixed terms for treatment, FEV₁ % predicted category, number of exacerbations in the previous year category, the respective baseline value, smoking status, prior ICS use, country, time-point, and treatment by time-point interaction. SGRQ-C responder rates were analyzed for each defined timepoint using a logistic regression model with fixed terms for treatment, FEV₁ % predicted category, number of exacerbations in the previous year category, smoking status, prior ICS use, and country. For details of biomarker analyses please refer to the earlier methodological manuscript.

Results

A total of 1,765 patients were randomized to 223 sites in 16 countries (Bulgaria, Czech Republic, Germany, Hungary, Latvia, Lithuania, Republic of Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, South Korea, Spain, Ukraine, and UK). The full analysis population (FAP: patients receiving ≥1 dose of study treatment and having ≥1 post-baseline exacerbation assessment) and safety population (patients receiving ≥1 dose of study treatment) were identical; and comprised 587, 588 and 590 patients in FP/FORM 500/20 µg, FP/FORM 250/10 µg and FORM arms, respectively. Patient disposition is summarized in Figure 1. There were fewer early discontinuations among patients randomized to FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with those receiving FORM (26.1%; Figure 2). A post hoc analysis of time to discontinuation indicated that FORM-treated patients discontinued earlier than those treated with FP/FORM 500/20 µg (hazard ratio [HR]: 0.77; P=0.029), but not FP/FORM 250/10 µg (HR: 0.90; P=0.348). Baseline demographic and disease characteristics of the randomized subjects were well balanced across treatment groups and are summarized in Table 1. A post hoc analysis showed a similar population distribution of eosinophil counts in each treatment group (Supplementary materials, Table S2).

Efficacy

Exacerbations

A high proportion of patients (~59%) experienced no exacerbations during the course of the study despite reporting at least 1 moderate/severe event in the prior year. No difference was seen in the annualized rate of moderate/severe COPD exacerbations between either FP/FORM arm compared with FORM (primary endpoint) (Table 2). In view of the sequential testing procedure employed and the non-significant result for the primary endpoint, subsequent inferential analyses should be considered exploratory in nature. No difference was seen in the time to moderate/severe exacerbations (Table 2). In patients with at least 2 moderate/severe COPD exacerbations in the year preceding the study, there was a 21% reduction in
the rate of moderate/severe events with FP/FORM 500/20 µg versus FORM that marginally failed to achieve significance at the 5% level (rate ratios [RR]: 0.79 [95% CI: 0.61, 1.03]; P=0.084); whereas exacerbation rates were similar for FP/FORM 250/10 µg and monotherapy (RR: 1.09 [95% CI: 0.85, 1.40]; P=0.484). Of note, even in this subpopulation of reported frequent exacerbators, almost 50% of patients experienced no exacerbation events throughout the entire study.

In view of the above results, a series of post hoc analyses were conducted in subgroups whereby the overall FAP population was dichotomized using baseline blood eosinophil cut-offs of 2%, 3% and 4% (Supplementary materials, Table S3). Exacerbation risk reduction with FP/FORM versus FORM was found to be no greater in any of the patient subgroups with a higher blood eosinophil count. Additionally, a graded increase in exacerbation rates in FORM-treated patients with increasing eosinophil counts (≥2%, ≥3%, ≥4%) was not seen.

**Lung function**

Average pre- and 1-hour post-dose FEV\textsubscript{1} and FVC over the course of the study were greater with FP/FORM 500/20 µg than FORM. With FP/FORM 250/10 µg, post-dose FEV\textsubscript{1} and FVC exceeded that with monotherapy (Table 3). Differences between FP/FORM and FORM in these parameters at week 52 were similar to differences in the average values between treatments over the course of the study, albeit were magnified at week 52 by approximately a further 10 mL for FEV\textsubscript{1} and 25 mL for FVC.

**Other efficacy endpoints**

Approximately 48% of patients experienced no EXACT-defined exacerbation events throughout the study duration. There was a 13% reduction in the annualized rate of EXACT exacerbations with FP/FORM 500/20 µg versus FORM that approached significance at the 5% level, whereas EXACT
Exacerbation rates were similar for FP/FORM 250/10 µg and FORM (Table 4).

SGRQ-C scores showed modest changes from baseline during the study across all treatment arms (Figure 3). Average SGRQ-C scores over the treatment period were significantly lower (improved) in the FP/FORM 500/20 µg arm versus FORM. The responder analyses at weeks 6, 23 and 52, with response defined per the minimum clinically important improvement threshold of −4 units23 (and with imputation of “non-response” for early discontinuations), indicated a greater likelihood of response with FP/FORM 500/20 µg than FORM (odds ratios [OR] [at weeks 6, 23 and 52] ≥1.28; \( P=0.054 \)). Differences between FP/FORM 250/10 µg and FORM were evident only at the week 6 time point (OR =1.31; \( P=0.036 \)).

The E-RS total score showed greater reductions in symptom scores with both FP/FORM 500/20 µg and 250/10 µg versus FORM (treatment difference −0.47 units \( P=0.039 \)).

Table 1 Patient demographic and baseline COPD characteristics (full analysis population)

<table>
<thead>
<tr>
<th></th>
<th>FP/FORM 500/20 µg</th>
<th>FP/FORM 250/10 µg</th>
<th>FORM 12 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>63.8 (7.92)</td>
<td>63.0 (7.81)</td>
<td>64.0 (7.87)</td>
</tr>
<tr>
<td>Gender (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male/female</td>
<td>75.5/24.5</td>
<td>72.6/27.4</td>
<td>75.9/24.1</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>98.1</td>
<td>95.9</td>
<td>97.1</td>
</tr>
<tr>
<td>Other (%)</td>
<td>1.9</td>
<td>4.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Duration COPD (years), mean (SD)</td>
<td>8.1 (6.05)</td>
<td>7.8 (5.86)</td>
<td>8.65 (6.91)</td>
</tr>
<tr>
<td>Smoking status, current/ex (%)</td>
<td>45.7/54.3</td>
<td>49.1/50.9</td>
<td>50.0/50.0</td>
</tr>
<tr>
<td>Smoking exposure (pack-years), mean (SD)</td>
<td>39.1 (19.5)</td>
<td>39.2 (20.1)</td>
<td>40.2 (21.0)</td>
</tr>
<tr>
<td>Pre-bronchodilator FEV\textsubscript{1} % predicted, mean (SD)</td>
<td>35.6 (8.51)</td>
<td>35.9 (8.31)</td>
<td>35.7 (8.81)</td>
</tr>
<tr>
<td>Post-bronchodilator FEV\textsubscript{1} % predicted, mean (SD)</td>
<td>37.8 (7.88)</td>
<td>38.0 (7.74)</td>
<td>37.7 (7.95)</td>
</tr>
<tr>
<td>FEV\textsubscript{1} reversibility (%)</td>
<td>7.7 (12.13)</td>
<td>7.4 (12.76)</td>
<td>7.4 (13.46)</td>
</tr>
<tr>
<td>Post-bronchodilator FEV\textsubscript{1}/FVC ratio (%)</td>
<td>41.4 (9.69)</td>
<td>42.3 (10.07)</td>
<td>42.1 (9.69)</td>
</tr>
<tr>
<td>Moderate or severe exacerbation frequency in past year, by category (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2 events</td>
<td>71.0</td>
<td>70.4</td>
<td>70.7</td>
</tr>
<tr>
<td>≥2 events</td>
<td>29.0</td>
<td>29.6</td>
<td>29.3</td>
</tr>
<tr>
<td>Time since last exacerbation (days), mean (SD)</td>
<td>131.8 (93.07)</td>
<td>136 (95.50)</td>
<td>143.3 (98.33)</td>
</tr>
<tr>
<td>SGRQ-C score (units), mean (SD)</td>
<td>53.9 (17.94)</td>
<td>53.5 (17.30)</td>
<td>54.8 (17.63)</td>
</tr>
<tr>
<td>Rescue use (occasions/day), mean (SD)</td>
<td>2.3 (1.77)</td>
<td>2.3 (1.79)</td>
<td>2.3 (1.81)</td>
</tr>
<tr>
<td>COPD medication, (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICS</td>
<td>14.1</td>
<td>14.6</td>
<td>14.2</td>
</tr>
<tr>
<td>LABA</td>
<td>21.6</td>
<td>18.4</td>
<td>25.3</td>
</tr>
<tr>
<td>ICS/LABA</td>
<td>59.5</td>
<td>62.4</td>
<td>58.3</td>
</tr>
<tr>
<td>LAMA</td>
<td>60.0</td>
<td>60.2</td>
<td>59.7</td>
</tr>
<tr>
<td>PDE4 inhibitors</td>
<td>0.7</td>
<td>1.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Xanthines</td>
<td>27.4</td>
<td>31.5</td>
<td>32.7</td>
</tr>
</tbody>
</table>

Abbriviations: COPD, chronic obstructive pulmonary disease; FEV\textsubscript{1}, forced expiratory volume in 1 s; FP, fluticasone propionate; FORM, formoterol fumarate; FVC, forced vital capacity; SGRQ-C, St George’s Respiratory Questionnaire for COPD; ICS, inhaled corticosteroid; LABA, long-acting \( \beta \)-agonist; LAMA, long-acting muscarinic antagonist; PDE4, inhibitor, phosphodiesterase type 4 inhibitor.

Table 2 Moderate/severe exacerbations analysis (full analysis population)

<table>
<thead>
<tr>
<th></th>
<th>FP/FORM 500/20 µg</th>
<th>FP/FORM 250/10 µg</th>
<th>FORM 12 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of moderate/severe exacerbation events (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>56.7</td>
<td>59.9</td>
<td>60.0</td>
</tr>
<tr>
<td>1</td>
<td>28.1</td>
<td>25.0</td>
<td>22.7</td>
</tr>
<tr>
<td>2</td>
<td>10.4</td>
<td>9.0</td>
<td>10.5</td>
</tr>
<tr>
<td>≥3</td>
<td>4.8</td>
<td>6.1</td>
<td>6.8</td>
</tr>
<tr>
<td>Rate moderate/severe exacerbations (events/patient/year)</td>
<td>0.81</td>
<td>0.81</td>
<td>0.87</td>
</tr>
<tr>
<td>Rate ratio (95% CIs) versus FORM</td>
<td>0.93 (0.79, 1.10)</td>
<td>0.93 (0.79, 1.10)</td>
<td>( P=0.402 )</td>
</tr>
<tr>
<td>Time to first moderate/severe exacerbation</td>
<td>1.02 (0.86, 1.23)</td>
<td>0.96 (0.80, 1.16)</td>
<td>( P=0.635 )</td>
</tr>
</tbody>
</table>

Abbriviations: FP, fluticasone propionate; FORM, formoterol fumarate.
and \(-0.52\) units \(P=0.021\), respectively). The E-RS breathlessness subscale indicated lower dyspnea scores with combination treatment versus FORM (treatment difference \(-0.22 \ [P=0.066]\) and \(-0.27 \ [P=0.024]\)) for FP/FORM 500/20 \(\mu g\) and 250/10 \(\mu g\), respectively. Patients with sleep disturbance at baseline gained \(-11\%–12\%\) additional awakening-free nights with all treatments over the course of the study, although no between-treatment differences were noted.

A post hoc analysis of time to first CID revealed a prolonged time to event occurrence with FP/FORM 500/20 \(\mu g\) and 250/10 \(\mu g\) versus FORM (hazard ratios 0.77 \([P=0.001]\) and 0.88 \([P=0.044]\)), respectively (Figure 4). Similar results were obtained for two other exploratory definitions of CID.

Biomarkers
Changes in SP-D and CCL-18 from baseline to week 6 are summarized in Supplementary materials, Tables S4 and S5, respectively. No between-treatment differences were observed for either biomarker, nor were associations with efficacy (for SP-D) or safety (for CCL-18) outcomes evident.

Safety
An overall summary of adverse events, and a summary of the most commonly affected organ systems, are presented in Tables 5 and 6, respectively, while a summary of common individual adverse events is presented in Supplementary materials, Table S6. Event frequencies were generally similar across treatment groups. Oral fungal infections were reported by 5 to 6 patients in all treatment groups, as well as diabetic/hyperglycemic events. None of the latter was considered related to treatment by investigators. There were no reports of skin thinning or bruising. Radiologically confirmed pneumonia in accordance with BTS standards, 17 (2.9%), 23 (3.9%) and 11 (1.9%) of patients in the corresponding groups were diagnosed with pneumonia. There were no overt differences between-treatments observed in the occurrence of serious cardiovascular events.

Assessments of maximal acute \(\beta_2\)-agonist-induced effects (decreases in serum potassium and diastolic blood pressure, increases in heart rate, QTc interval and systolic blood pressure) revealed no evidence of a greater effect with FP/FORM 500/20 \(\mu g\) than with the other two treatments incorporating a lower formoterol dose. Furthermore, 24-hour Holter monitoring also revealed no relevant between-treatment differences. Estimation of 24-hour urinary-free cortisol corrected for

Table 4 EXACT exacerbations analysis (full analysis population)

<table>
<thead>
<tr>
<th></th>
<th>FP/FORM 500/20 (\mu g)</th>
<th>FP/FORM 250/10 (\mu g)</th>
<th>FORM 12 (\mu g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of moderate/severe exacerbation events (%)</td>
<td>48.4</td>
<td>47.1</td>
<td>48.5</td>
</tr>
<tr>
<td>1</td>
<td>28.3</td>
<td>27.6</td>
<td>27.8</td>
</tr>
<tr>
<td>2</td>
<td>12.6</td>
<td>12.4</td>
<td>11.7</td>
</tr>
<tr>
<td>(\geq 3)</td>
<td>10.7</td>
<td>12.9</td>
<td>12.0</td>
</tr>
<tr>
<td>Rate moderate/severe exacerbations (events/patient/year)</td>
<td>1.02</td>
<td>1.16</td>
<td>1.17</td>
</tr>
<tr>
<td>Rate ratio (95% CIs) versus FORM</td>
<td>0.87 (0.75, 1.01)</td>
<td>0.99 (0.85, 1.14)</td>
<td>P=0.077</td>
</tr>
</tbody>
</table>

Abbreviations: EXACT, EXAcerbations of Chronic pulmonary disease Tool; FP, fluticasone propionate; FORM, formoterol fumarate.
creatinine (24-hour UFCC) at weeks 6 and 52 in a subgroup of subjects not on inhaled corticosteroids pre-study demonstrated a similar mean reduction from baseline in 24-hour UFCC in both FP/FORM arms but no change from baseline in the FORM group.

Fifty-three patients died (21 [3.6%] on FP/FORM 500/20 µg; 19 [3.2%] on FP/FORM 250/10 µg; 13 [2.2%] on FORM). None of the deaths was reported as related to the study medication by the treating physician. Three patients died following pneumonia: 1 and 2 on FP/FORM 500/20 µg and 250/10 µg, respectively, while further 2 patients, 1 in each FP/FORM group, died following other lower respiratory tract infections (bronchitis and lower respiratory tract infection).

Discussion

The study did not meet its primary endpoint: there was a non-significant 7% reduction in the rate of moderate/severe exacerbations with FP/FORM (both dose levels) compared with FORM. This was a somewhat surprising result since the components/doses within FP/FORM have proven to be effective in previous COPD studies.

However, it is also relevant that other trials of ICS/LABA combinations have failed to show exacerbation risk reduction versus LABA monotherapy. In the light of earlier unsuccessful ICS/LABA trials, several steps were taken to mitigate such an outcome: patients had severe airways obstruction; documentation confirming an exacerbation within the past 12 months was required for enrolment; “recent” exacerbations did not preclude enrolment other than if occurring during the run-in or at screening; a tiotropium run-in was employed to facilitate retention of as many patients as possible during the pre-randomization phase (<6% of subjects discontinued during the run-in); the study was of 12 months duration, thereby mitigating for seasonal variations in exacerbation rates; and the EXACT PRO was used to encourage detection of a greater proportion of unreported exacerbation events, as per the recent FORWARD study. Furthermore, the pooled exacerbation rate was monitored on an ongoing basis and additional subjects were enrolled via a protocol amendment to preserve study power when it became apparent that the observed overall exacerbation rate was lower than initially predicted.

The patients enrolled had a mean post-bronchodilator FEV₁ of 38% predicted, were symptomatic (mean SGRQ-C score of 54 units) and reported 1.4 moderate/severe exacerbations on average over the previous year. Furthermore, over 60% had ≥2% blood eosinophils at baseline. These characteristics are in keeping with recent ICS/LABA exacerbation studies, albeit airways obstruction was particularly severe in our study. Thus, the population enrolled would have been expected to be prone to exacerbations and to differentiate the protective effects of ICS/LABA versus LABA in this regard. Interestingly, however, in the recent TRILOGY trial, exacerbation risk reduction with triple therapy versus ICS/LABA was evident only in patients with severe (≥30%–<50% predicted FEV₁), but not very severe airways obstruction (<30% predicted). This raises the question as to whether the greater severity of airway obstruction in our study in comparison to several previous ICS/LABA trials was implicated in the observed lack of effect upon exacerbations. To our knowledge, published subgroup analyses of patients with severe and very severe airways obstruction are not available for previous ICS/LABA trials.

Differential withdrawal rates may also be implicated in the failure to show exacerbation risk reduction with FP/FORM as it may have led to a healthy survivor effect. A greater proportion of patients discontinued prematurely in the FORM arm, with discontinuation occurring sooner in these patients than those discontinuing FP/FORM, particularly in the 500/20 µg group. SGRQ-C scores were almost 10 units higher on average in patients who discontinued prematurely (60.3 units) than in those who completed the
study (50.7 units). Furthermore, patients discontinuing early reported overall worsening of SGRQ-C scores during the treatment period, unlike patients who remained in the study whose health status improved on average. The loss of patients with markedly impaired and deteriorating health status, prone to exacerbation and doing so recurrently, may have reduced the likelihood of demonstrating a treatment effect as reported in other studies. The TORCH study was illuminating in this regard: placebo-treated patients remaining in the study for ≤6 months experienced 6.8 exacerbations/year compared with 0.9 exacerbations/year in those with over 30 months exposure. Placebo-treated patients with exposures between these two extremes showed a stepwise reduction in exacerbation rates.

A further contributory factor to the observed results may have been under-reporting of exacerbations, an issue, which is well recognized: in cohorts of trained and regularly reviewed British, Canadian and Chinese patients, 50%–70% of exacerbations have been unreported. It has been postulated that COPD patients may under-report exacerbations given their familiarity with changing symptom levels and acceptance of their disease. As previously mentioned, we sought to reduce exacerbation under-reporting by employing the EXACT PRO to trigger patient–physician interactions. Although Wedzicha et al used the diary in a similar manner in their successful beclomethasone/formoterol trial, a limitation of this approach is the modest concordance between exacerbations defined on the basis of healthcare utilization (HCU) and EXACT exacerbations: 2 separate studies noted that only a third of HCU events fulfilled EXACT exacerbation criteria.

Our post hoc analyses of moderate/severe exacerbation rates in blood eosinophil subgroups also hint at exacerbation under-reporting. Exacerbation rates in FORM-treated patients did not increase with increasing eosinophil levels. Additionally, the exacerbation RR with FP/FORM 500/20 µg versus FORM was −1 whether in patients with ≥2%, ≥3% or ≥4% eosinophils. These data are inconsistent with a growing body of recent data. The latter have indicated a tendency to increased exacerbation rates in bronchodilator-treated COPD patients with prior exacerbations as blood eosinophil levels rise; and greater exacerbation risk reduction with ICS/LABA versus bronchodilator treatment with increasing eosinophil counts. Although a prospectively designed trial to confirm these observations is yet lacking, a recent editorial noted the consistency of such findings across several trials of different design.

The above observations may in conjunction have contributed to a particularly low exacerbation rate in the FORM arm in our study (0.87 events/patient/year), which was especially notable given the disease severity of the study population. It is recognized that exacerbation rates have diminished over time in randomized trials similar to our own, which may reflect improvements in patient care. However,

Table 5 Overall incidence of adverse events (safety population)

<table>
<thead>
<tr>
<th>Subjects with ≥1 adverse event (%)</th>
<th>FP/FORM 500/20 µg</th>
<th>FP/FORM 250/10 µg</th>
<th>FORM 12 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with ≥1 adverse event (%)</td>
<td>42.2</td>
<td>44.2</td>
<td>40.7</td>
</tr>
<tr>
<td>Subjects with ≥1 severe adverse event (%)</td>
<td>9.7</td>
<td>9.0</td>
<td>8.1</td>
</tr>
<tr>
<td>Subjects with ≥1 serious adverse event (%)</td>
<td>10.7</td>
<td>12.8</td>
<td>9.8</td>
</tr>
<tr>
<td>Subjects with ≥1 adverse event leading to discontinuation (%)</td>
<td>4.1</td>
<td>5.8</td>
<td>4.4</td>
</tr>
</tbody>
</table>

Note: *Serious adverse events defined as fatal, life-threatening, (prolongation of existing) hospitalization, persistent/significant incapacity, requires intervention to prevent permanent impairment.

Abbreviations: FP, fluticasone propionate; FORM, formoterol fumarate.

Table 6 Incidence (%) of frequent adverse events by system organ class (safety population)

<table>
<thead>
<tr>
<th>System organ class</th>
<th>FP/FORM 500/20 µg</th>
<th>FP/FORM 250/10 µg</th>
<th>FORM 12 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>15.7</td>
<td>19.9</td>
<td>18.0</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>10.4</td>
<td>9.7</td>
<td>9.7</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>8.2</td>
<td>7.8</td>
<td>5.8</td>
</tr>
<tr>
<td>Investigations</td>
<td>3.7</td>
<td>6.5</td>
<td>5.4</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>6.1</td>
<td>4.6</td>
<td>4.1</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>4.6</td>
<td>3.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>4.9</td>
<td>4.9</td>
<td>3.7</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>4.9</td>
<td>4.3</td>
<td>3.9</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>2.9</td>
<td>3.7</td>
<td>2.9</td>
</tr>
</tbody>
</table>

Abbreviations: FP, fluticasone propionate; FORM, formoterol fumarate.
the exacerbation rate in FORM-treated patients in our study was ~20%–30% lower than the corresponding rates on LABA treatment in three similar, recent trials. Indeed, among all comparable ICS/LABA exacerbation studies, only Calverley et al’s study of beclomethasone/formoterol reported lower exacerbation rates in LABA-treated patients than in the present study. By contrast, the exacerbation rate with FP FORM in our study was very consistent with those recently reported for ICS/LABA treatment in the FORWARD trial and replicate fluticasone furoate/vilanterol studies.

A post hoc analysis of time to CID was undertaken given concerns as to the impact of unreported exacerbations, differential drop-out rates and a healthy survivor effect upon the primary endpoint result. The same definition recently proposed by Singh et al was employed. The minimum clinically important difference thresholds for lung function and SGRQ-C incorporated within this definition are well established, and deterioration of lung function and health status is associated with poorer long-term outcomes in COPD as moderate/severe exacerbations, the component of this composite measure. It is thus a coherent endpoint to assess treatment benefit in COPD. A significantly slower time to CID was observed for both FP FORM dose levels versus FORM. Further studies to validate this composite measure, to establish its capacity to differentiate treatments, and define its relationship to prognosis will be required. An initial post hoc analysis of the ECLIPSE and TORCH trials suggests that CID “positivity” is indeed linked to mortality.

Pneumonia was reported more frequently with FP FORM compared with FORM monotherapy (approximately a 2-fold difference), albeit the absolute difference in incidence was small (~1%). These findings, and the incidence of pneumonia with FP FORM, are consistent with previous reports. A strength of our study is that pneumonia was identified in accordance with BTS criteria, including radiographic confirmation wherever feasible. There were 5 deaths following pneumonia or other lower respiratory tract infections in this study (2 on FP FORM 500/20 µg and 3 on FP FORM 250/10 µg), and overall a slightly increased number of all cause deaths on combination versus monotherapy. Given these findings, albeit in patient numbers too small to permit definitive conclusions, the findings of a recent, large National Institutes of Health-sponsored review are of interest: Festic and Scanlon reviewed randomized controlled trials (RCTs) including ~15,000 ICS-treated patients and observational studies involving ~50,000 ICS-treated patients. Pneumonia risk was increased 2- to 3-fold in RCTs on ICS versus non-ICS treatments, and to a lesser extent, in observational studies. However, pneumonia-related mortality and total mortality were unchanged on ICS in RCTs and were decreased in the majority of observational studies. The apparent contradiction between increased pneumonia risk and unchanged/decreased mortality led the authors to speculate that pneumonia may result from the local immunosuppressive effects of ICS, which may, however, modulate the severity of pneumonia via their anti-inflammatory effects. Two recent independent observational studies provide support for this notion.

As with pneumonia, other adverse events, biochemical changes and acute pharmacodynamic effects showed no evidence of a dose response between the 500/20 µg and 250/10 µg FP FORM dose levels. Similarly, from an efficacy perspective, and as anticipated, few overt between-dose level differences were seen. Nonetheless, although the study did not confirm the efficacy of FP FORM, it did suggest the higher FP FORM dose might be more appropriate in COPD patients, subject to confirmation in future studies. In comparison to FORM, there was an apparent trend in favor of the higher FP FORM dose in terms of risk reduction in frequent exacerbators, lung function, EXACT exacerbations, SGRQ-C responders and time to CID. Whether these incremental benefits are due to the increased fluticasone propionate or formoterol dose in FP FORM 500/20 µg versus the 250/10 µg dose cannot be definitively ascertained. However, the significant increases in pre-morning dose FEV₁ and FVC with FP FORM 500/20 µg, but not 250/10 µg, versus FORM may suggest a relevant contribution from its ICS component.

**Conclusion**

FP FORM did not reduce exacerbation rates in comparison to FORM in patients with COPD and a history of prior exacerbations. Numerical benefits were, however, observed in favor of FP FORM 500/20 µg versus FORM for a number of secondary variables including pre- and post-dose lung function, EXACT exacerbations, SGRQ-C, and ER-S total and breathlessness scores. Few efficacy differences were evident between FP FORM 250/10 µg and FORM. Pneumonia was more frequent in FP FORM-treated patients, although the absolute difference in incidence was small. Adverse event profiles were otherwise similar between treatments.

**Acknowledgments**

The authors wish to thank all patients, investigators, sites, contract research organization staff and sponsor staff for their involvement in the study. Flutiform is a registered trade
mark of Jagotec AG. Atimos and Modulite are registered trademarks of Chiesi Farmaceutici S.p.A. Spiriva is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG.

The study was funded by Mundipharma Research Limited. Editorial assistance to prepare this manuscript was provided by MD Medical Communications Limited, and was funded by Mundipharma Research Limited.

**Author contributions**

All authors reviewed this manuscript, take responsibility for the integrity of the data herein, drafting and revising the paper, meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have given final approval to the version to be published.

**Disclosure**

Professor Papi reports grants, personal fees, non-financial support and other from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Takeda, Mundipharma, TEVA; personal fees and non-financial support from Menarini, Novartis, Zambon; and grants from Sanofi, outside the submitted work. Dr Koroknai is an employee of PAREXEL, the contract research organization contracted to perform the study. Ms McAulay, Dr Dalvi and Dr Overend are employees of Mundipharma Research Limited, Cambridge, UK. Dr Mersmann is an employee of Mundipharma Research GmbH & Co. KG, Germany. Professor Dokic, Dr Tzimas, Dr Mészáros, and Dr Olech-Cudzik have no conflicts of interest to declare. The authors report no other conflicts of interest in this work.

**References**


International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal